Patents Assigned to ioGenetics, LLC
  • Patent number: 11434259
    Abstract: The present invention relates to vaccine compositions and therapeutic interventions for treating and preventing infections and diseases caused by flaviviruses, including Zika, dengue, and Usutu virus. It also relates to compositions and methods for diagnosis and differential diagnosis of flaviviruses and co-endemic pathogens.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: September 6, 2022
    Assignee: IOGENETICS, LLC
    Inventors: Robert D. Bremel, Jane Homan, Michael Imboden
  • Publication number: 20210265008
    Abstract: The present invention provides methods and systems for identifying and classifying patterns comprising the T cell exposed motifs and the frequencies of such motifs in collections of proteins that make up the human proteome, immunoglobulinome, T cell receptor repertoire or microbiome, and other proteomes of environmental of microbial origin, or subsets thereof. It further provides graphical representations that facilitate comparisons of T cell exposed motif patterns between samples or between time points. The present invention also provides methods and systems for identifying and classifying patterns in repertoires of cells including receptor bearing cells and cells of tissue samples and detecting patterns of utility in diagnosis and monitoring of health and disease.
    Type: Application
    Filed: May 9, 2019
    Publication date: August 26, 2021
    Applicant: Iogenetics, LLC
    Inventors: Robert D. BREMEL, Jane HOMAN
  • Patent number: 11069427
    Abstract: This invention relates to the identification of peptidase cleavage sites in proteins and in particular to identification protease cleavage by the endopeptidases. The present invention utilizes a bioinformatic methodology for prediction of peptidase cleavage sites based on principal component analysis and based on training sets obtained by experimental protein cleavage. This invention is not limited to training sets derived from CSL approaches, nor to any other experimental determination of cleavage site.
    Type: Grant
    Filed: June 9, 2014
    Date of Patent: July 20, 2021
    Assignee: IOGENETICS, LLC
    Inventor: Robert D. Bremel
  • Patent number: 10799582
    Abstract: The present invention provides a means to prepare a product from domestic animal milk, blood or eggs which comprises an array of T-cell exposed motifs similar in identity, distribution and concentration to those found in human immunoglobulin variable regions and to prepare and apply the product as an immune modulating agent for administration either as a nutritional supplement or as a pharmaceutical product.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: October 13, 2020
    Assignee: IOGENETICS, LLC
    Inventors: Robert D. Bremel, Jane Homan
  • Patent number: 10755801
    Abstract: The present invention provides methods and systems for identifying and classifying epitopes and use of that information to analyze proteins and peptides within proteins, especially potential epitopes, and to use the information to design synthetic peptides and proteins, analyze biopharmaceutical proteins, and diagnose autoimmune conditions. Peptides which are bound in MHC grooves comprise two sets of amino acids: those that face inwards into the groove and determine the binding affinity to the MHC molecule (the groove exposed motifs or GEM) and those which do not interact with the groove but rather are on the obverse side exposed outwardly to the T-cells (the T-cell exposed Motifs or TCEM). The present invention utilizes information related to the identity and physiochemical characteristics of the GEM and TCEM.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: August 25, 2020
    Assignee: IOGENETICS, LLC
    Inventors: Robert D. Bremel, Jane Homan, Michael Imboden
  • Patent number: 10706955
    Abstract: This invention relates to processes for identifying peptide and polypeptide ligands for a binding partner by using principal component analysis of amino acids to derive vectors describing amino acid subsets corresponding to peptides with known binding affinities and then using this information in a neural network modeling process to derive binding prediction equations. These binding prediction equations are then used in the analysis of subsets of amino acids from a target source to identify peptides or polypeptides ligands in the target source that have affinity for a binding partner.
    Type: Grant
    Filed: March 21, 2011
    Date of Patent: July 7, 2020
    Assignee: IOGENETICS, LLC
    Inventors: Robert D. Bremel, Jane Homan
  • Publication number: 20170039314
    Abstract: This invention relates to the identification of peptide binding to ligands, and in particular to identification of epitopes expressed by microorganisms and by mammalian cells. The present invention provides polypeptides comprising the epitopes, and vaccines, antibodies and diagnostic products that utilize or are developed using the epitopes.
    Type: Application
    Filed: September 13, 2012
    Publication date: February 9, 2017
    Applicant: IOGENETICS, LLC
    Inventors: Rober D. Bremel, Jane Homan
  • Publication number: 20150284452
    Abstract: The present invention relates antimicrobial compositions, and in particular to antigen binding proteins comprising one or more domains that provide antimicrobial activity.
    Type: Application
    Filed: November 13, 2013
    Publication date: October 8, 2015
    Applicant: IOGENETICS, LLC
    Inventors: Robert Duane Bremel, Jane Homan, Michael Imboden, Brendan Keough
  • Patent number: 8703134
    Abstract: The present invention relates to fusion proteins comprising a microorganism targeting molecule (e.g., immunoglobulin) and a biocide. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in diverse fields.
    Type: Grant
    Filed: February 6, 2013
    Date of Patent: April 22, 2014
    Assignees: ioGenetics, LLC, Arizona Board of Regents on Behalf of the University of Arizona
    Inventors: Michael Imboden, Michael Riggs, Deborah A. Schaefer, Jane Homan, Robert D. Bremel
  • Publication number: 20130330335
    Abstract: This invention relates to the identification of peptide binding to ligands, and in particular to identification of epitopes expressed by microorganisms and by mammalian cells. The present invention provides polypeptides comprising the epitopes, and vaccines, antibodies and diagnostic products that utilize or are developed using the epitopes.
    Type: Application
    Filed: March 21, 2011
    Publication date: December 12, 2013
    Applicant: IOGENETICS, LLC
    Inventors: Robert D. Bremel, Jane Homan
  • Publication number: 20130230516
    Abstract: The present invention relates to fusion proteins comprising a microorganism targeting molecule (e.g., immunoglobulin) and a biocide. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in diverse fields.
    Type: Application
    Filed: February 6, 2013
    Publication date: September 5, 2013
    Applicants: Arizona Board of Regents on behalf of the University of Arizona, ioGenetics, LLC
    Inventors: Michael Imboden, Michael Riggs, Deborah A. Schaefer, Jane Homan, Robert D. Bremel
  • Patent number: 8394379
    Abstract: The present invention relates to fusion proteins comprising a microorganism targeting molecule (e.g., immunoglobulin) and a biocide. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in diverse fields.
    Type: Grant
    Filed: January 13, 2010
    Date of Patent: March 12, 2013
    Assignee: ioGenetics, LLC
    Inventors: Michael Imboden, Michael Warren Riggs, Deborah A. Schaefer, Jane Homan
  • Publication number: 20100183611
    Abstract: The present invention relates to fusion proteins comprising a microorganism targeting molecule (e.g., immunoglobulin) and a biocide. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in diverse fields.
    Type: Application
    Filed: January 13, 2010
    Publication date: July 22, 2010
    Applicants: IOGENETICS, LLC., ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
    Inventors: Michael Imboden, Michael Riggs, Deborah A. Schaefer, Jane Homan
  • Publication number: 20100111976
    Abstract: The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing).
    Type: Application
    Filed: September 24, 2009
    Publication date: May 6, 2010
    Applicant: IOGENETICS, LLC
    Inventors: Michael Imboden, Jane Homan, Robert D. Bremel
  • Publication number: 20100034824
    Abstract: The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzyme) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing).
    Type: Application
    Filed: August 5, 2009
    Publication date: February 11, 2010
    Applicants: IOGENETICS, LLC, THE ARIZONA BOARD OF REGENTS
    Inventors: Michael Imboden, Michael Riggs, Deborah A. Schaefer
  • Patent number: 7566447
    Abstract: The present invention relates to the use of biocide (e.g., bactericidal enzyme) to target pathogens. In particular, the present invention provides biocides for use in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., water purification).
    Type: Grant
    Filed: October 20, 2005
    Date of Patent: July 28, 2009
    Assignees: Iogenetics, LLC, The Arizona Board of Regents on Behalf of the University of Arizona
    Inventors: Jane Homan, Michael Imboden, Michael Riggs, Stephane Carryn, Deborah A. Schaefer
  • Publication number: 20090098121
    Abstract: The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing).
    Type: Application
    Filed: October 19, 2007
    Publication date: April 16, 2009
    Applicant: ioGenetics, LLC
    Inventors: Michael Imboden, Jane Homan, Robert D. Bremel
  • Publication number: 20080269122
    Abstract: The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing).
    Type: Application
    Filed: October 19, 2007
    Publication date: October 30, 2008
    Applicant: ioGenetics, LLC
    Inventors: Michael Imboden, Jane Homan, Robert D. Bremel
  • Publication number: 20080267943
    Abstract: The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing).
    Type: Application
    Filed: October 19, 2007
    Publication date: October 30, 2008
    Applicant: ioGenetics, LLC
    Inventors: Michael Imboden, Jane Homan, Robert D. Bremel
  • Patent number: 7300790
    Abstract: The present invention relates to non-vaccinal and non-pharmacologic compositions and methods for controlling complex retroviral infections. In particular, the present invention provides transgenic animals expressing a transdominant negative Rex gene product that inhibits retroviral replication.
    Type: Grant
    Filed: January 23, 2004
    Date of Patent: November 27, 2007
    Assignee: ioGenetics, LLC
    Inventors: Kurt Eakle, Thomas Hope, Eun-A Choi, Jane Homan, Robert D. Bremel